Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro

Creative Commons License

Bilir A., Erguven M., Ermis E., Sencan M., YAZIHAN N.

JOURNAL OF GYNECOLOGIC ONCOLOGY, cilt.22, sa.4, ss.225-232, 2011 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 4
  • Basım Tarihi: 2011
  • Doi Numarası: 10.3802/jgo.2011.22.4.225
  • Dergi Adı: JOURNAL OF GYNECOLOGIC ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.225-232
  • Anahtar Kelimeler: Endometrial cancer, Imatinib mesylate, Lithium chloride, Medroxyprogesterone acetate, Midkine, CANCER, SARCOMA, CELLS
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: The aim of the study was to investigate whether lithium chloride and medroxyprogesterone acetate can potentiate the cytotoxicity of imatinib mesylate in human endometrial cancer in vitro and the effect of midkine in these therapies.